Estrogen Receptor-positive Breast Cancer
📧 Sign up to get email alerts when something new happens for Estrogen Receptor-positive Breast Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2021-04-23Clinical Trial Update: MEDI4736 and Tremelimumab in Treating Patients With Metastatic HER2 Negative Breast Cancer [Phase 2]
Phase 2 trial update evaluating MEDI4736 (durvalumab) and tremelimumab in metastatic HER2-negative breast cancer has completed with posted r…
-
CLINICAL_TRIALS trial_result · 2021-03-11Clinical Trial Update: Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer [Phase 2]
Phase II trial of the CDK inhibitor PD 0332991 (palbociclib) in various adult solid tumors including colon and breast cancers has completed …
-
CLINICAL_TRIALS trial_result · 2020-12-29Clinical Trial Update: Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Alobresib (Formerly GS-5829) in Adults With Advanced Solid Tumors and Lymphomas and in Combination With Exemestane or Fulvestrant in Adults With Estrogen Receptor Positive Breast Cancer [Phase 1]
Phase 1 study evaluating safety, tolerability, pharmacokinetics, and pharmacodynamics of alobresib (GS-5829) in adults with advanced solid t…
-
CLINICAL_TRIALS trial_result · 2020-10-01Clinical Trial Update: Letrozole and Metronomic Capecitabine in ER-positive HER2 Negative Advanced Breast Cancer (B-001 Study) [Phase 2]
Phase 2 clinical trial update evaluating letrozole with metronomic capecitabine in ER-positive, HER2-negative advanced/metastatic breast can…
-
CLINICAL_TRIALS trial_result · 2020-09-30Clinical Trial Update: Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure [Phase 2]
Phase 2 trial evaluating durvalumab in combination with endocrine therapy for ER+/HER2- breast cancer after an immune-attractant exposure; s…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2020-09-21Clinical Trial Update: Mucoadhesive Oral Wound Rinse in Preventing and Treating Stomatitis in Patients With ER- or PR-Positive Metastatic or Locally Recurrent Breast Cancer That Cannot be Removed by Surgery Receiving Everolimus [Phase 2]
Phase 2 clinical trial evaluating a mucoadhesive oral wound rinse to prevent and treat stomatitis in patients with ER- or PR-positive metast…
-
CLINICAL_TRIALS trial_result · 2020-04-28Clinical Trial Update: Biomarkers in Tissue Samples From Patients With Newly Diagnosed Breast Cancer Treated With Zoledronic Acid [NA]
A terminated clinical trial investigating biomarkers in tissue samples from newly diagnosed breast cancer patients treated with zoledronic a…
-
CLINICAL_TRIALS trial_result · 2020-02-11Clinical Trial Update: F-18 FES PET/CT in Measuring Hormone Expression in Patients With Primary, Recurrent, or Metastatic Breast Cancer Undergoing Endocrine-Targeted Therapy [NA]
Clinical trial assessing F-18 FES PET/CT to measure hormone expression in estrogen receptor–positive breast cancer during endocrine-targeted…
-
CLINICAL_TRIALS trial_result · 2020-01-27Clinical Trial Update: Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer [Phase 2]
Phase 2 clinical trial investigating letrozole in combination with imatinib mesylate for postmenopausal women with estrogen receptor–positiv…
-
CLINICAL_TRIALS trial_result · 2019-10-24Clinical Trial Update: Study to Evaluate Exemestane With and Without Entinostat (SNDX-275) in Treatment of Postmenopausal Women With Advanced Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating exemestane with or without entinostat (SNDX-275) in postmenopausal women with advanced estrogen receptor-p…
-
CLINICAL_TRIALS trial_result · 2019-02-01Clinical Trial Update: CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448) [Phase 1, Phase 2]
This document reports the completion of a Phase 1/Phase 2 clinical trial evaluating seviteronel, a CYP17 lyase and androgen receptor inhibit…
-
CLINICAL_TRIALS trial_result · 2018-10-17Clinical Trial Update: Pilot Study Estradiol Followed by Exemestane Hormone Receptor + Metastatic Breast Cancer [NA]
Pilot study evaluating estradiol followed by exemestane in hormone receptor-positive metastatic breast cancer; trial completed with posted r…
-
CLINICAL_TRIALS trial_result · 2018-07-27Clinical Trial Update: A Study of Abiraterone Acetate Plus Prednisone With or Without Exemestane in Postmenopausal Women With Estrogen Receptor-Positive (ER+) Metastatic Breast Cancer Progressing After Letrozole or Anastrozole Therapy [Phase 2]
Phase 2 trial evaluating abiraterone acetate plus prednisone with or without exemestane in postmenopausal women with estrogen receptor-posit…
-
CLINICAL_TRIALS trial_result · 2018-07-26Clinical Trial Update: Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer [Phase 2]
A phase 2 neoadjuvant trial of anastrozole plus pazopanib in stage II/III estrogen receptor-positive, HER2-negative breast cancer was termin…
-
CLINICAL_TRIALS trial_result · 2018-07-23Clinical Trial Update: MK2206 in Combination With Anastrozole, Fulvestrant, or Anastrozole and Fulvestrant in Treating Postmenopausal Women With Metastatic Breast Cancer [Phase 1]
Phase 1 trial evaluating MK-2206 in combination with anastrozole and/or fulvestrant in postmenopausal women with metastatic breast cancer; s…
-
CLINICAL_TRIALS trial_result · 2018-05-08Clinical Trial Update: Akt Inhibitor MK-2206 and Anastrozole With or Without Goserelin Acetate in Treating Patients With Stage II-III Breast Cancer [Phase 2]
Phase 2 trial evaluating MK-2206 with anastrozole, with or without goserelin acetate, in stage II-III breast cancer; the study was terminate…
-
CLINICAL_TRIALS trial_result · 2018-05-07Clinical Trial Update: Oral VT-464 in Patients With Castration-Resistant Prostate Cancer Previously Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer [Phase 2]
Phase 2 clinical trial update for VT-464 in patients with castration-resistant prostate cancer previously treated with enzalutamide, androge…
-
FDA approval · 2018-04-27FDA Approved: EXEMESTANE — Original Application (Cipla USA Inc.)
FDA approves Cipla USA Inc.'s generic Exemestane as an original ANDA approval (ANDA 210323).
-
CLINICAL_TRIALS research · 2018-04-13Clinical Trial Update: Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer [Phase 2]
Phase 2 clinical trial evaluating neoadjuvant letrozole in combination with chemotherapy for estrogen receptor-positive, HER2-negative breas…
-
CLINICAL_TRIALS trial_result · 2018-03-12Clinical Trial Update: Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery [Phase 2]
A Phase 2 trial evaluating pre-surgery chemotherapy with filgrastim in patients with HER2-positive breast cancer that could be surgically re…
-
CLINICAL_TRIALS trial_result · 2017-08-31Clinical Trial Update: Doxorubicin Hydrochloride, Cyclophosphamide, and Filgrastim Followed By Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Trastuzumab in Treating Patients With Breast Cancer Previously Treated With Surgery [Phase 2]
A Phase 2 trial evaluating a multi-drug regimen (doxorubicin hydrochloride, cyclophosphamide, filgrastim) followed by paclitaxel albumin-sta…
-
CLINICAL_TRIALS trial_result · 2017-06-06Clinical Trial Update: Hormone Therapy and Combination Chemotherapy Before and After Surgery in Treating Patients With Stage I-IIIA Breast Cancer [Phase 2]
Phase 2 trial of hormone therapy and combination chemotherapy before and after surgery for stage I-IIIA breast cancer was terminated; result…
-
CLINICAL_TRIALS trial_result · 2017-05-31Clinical Trial Update: A Study of Ridaforolimus (MK-8669) in Combination With Dalotuzumab (MK-0646) Compared to Standard of Care Treatment in Estrogen Receptor Positive Breast Cancer Patients (MK-8669-041 AM3) [Phase 2]
Phase 2 study evaluating ridaforolimus in combination with dalotuzumab versus standard of care in estrogen receptor-positive breast cancer h…
-
CLINICAL_TRIALS trial_result · 2017-05-04Clinical Trial Update: AKT Inhibitor in Oestrogen Positive Breast Cancer [Phase 2]
A Phase 2 clinical trial of an AKT inhibitor for estrogen receptor-positive breast cancer has completed enrollment.
-
CLINICAL_TRIALS trial_result · 2017-05-01Clinical Trial Update: Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women [Phase 2]
Phase 2 clinical trial comparing fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone in premenopausal women …